LONDON, Jan 16 (Reuters) - Weight-loss giant Novo Nordisk's [(NOVOb.CO)](https://www.reuters.com/markets/companies/NOVOb.CO) shares rose over 5% on Friday to a high last touched in October, driven by "encouraging" early U.S. prescription data for its Wegovy pill, which the firm hopes will help it regain ground in the obesity drug race.
[https://www.reuters.com/legal/litigation/novo-shares-jump-7-ahead-us-prescription-data-wegovy-pill-2026-01-16/](https://www.reuters.com/legal/litigation/novo-shares-jump-7-ahead-us-prescription-data-wegovy-pill-2026-01-16/)